Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study-Reference-Cited by-同舟云学术

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Published:2017-05-12 Issue:11 Volume:31 Page:2443-2448
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kumar S K^ORCID,Dimopoulos M A,Kastritis E,Terpos E,Nahi H,Goldschmidt H,Hillengass J,Leleu X,Beksac M^ORCID,Alsina M,Oriol A,Cavo M,Ocio E M,Mateos M V,O'Donnell E K,Vij R,Lokhorst H M,van de Donk N W C J,Min C,Mark T,Turesson I,Hansson M^ORCID,Ludwig H,Jagannath S,Delforge M,Kyriakou C,Hari P,Mellqvist U,Usmani S Z,Dytfeld D,Badros A Z,Moreau P,Kim K^ORCID,Otero P R,Lee J H,Shustik C,Waller D,Chng W J,Ozaki S,Lee J-J,de la Rubia J,Eom H S,Rosinol L,Lahuerta J J,Sureda A,Kim J S,Durie B G M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/leu2017138.pdf

Reference20 articles.

1. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122–1128.

2. Pulte D, Jansen L, Castro FA, Emrich K, Katalinic A, Holleczek B et al. Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. Br J Haematol 2015; 171: 189–196.

3. Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H et al. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J 2015; 5: e349.

4. Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA et al. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J 2016; 6: e401.

5. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467–472.

Cited by 255 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Laboratory practice is central to earlier myeloma diagnosis: Utilizing a primary care diagnostic tool and laboratory guidelines integrated into haematology services;British Journal of Haematology;2024-01-02

2. Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report;Oncohematology;2023-12-08

3. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials;Frontiers in Oncology;2023-12-07

4. Elotuzumab in the treatment of patients with refractory and relapsed multiple myeloma Experience of the Lapino Clinical Hospital Oncohematology Department;Oncohematology;2023-12-07

5. Th9/IL‐9 may participate in the pathogenesis of multiple myeloma;International Journal of Laboratory Hematology;2023-12-06